Mario Mascalchi
Overview
Explore the profile of Mario Mascalchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
220
Citations
3329
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Robertson J, Adanyeguh I, Bender B, Boesch S, Brunetti A, Cocozza S, et al.
Mov Disord
. 2025 Feb;
PMID: 39927598
Background: Spinocerebellar ataxia type 2 (SCA2) is a rare, inherited neurodegenerative disease characterized by progressive deterioration in both motor coordination and cognitive function. Atrophy of the cerebellum, brainstem, and spinal...
2.
Mascalchi M, Marzi C, Diciotti S
Signal Transduct Target Ther
. 2025 Jan;
10(1):18.
PMID: 39848967
No abstract available.
3.
De Luca G, Diciotti S, Mascalchi M
Arch Bronconeumol
. 2024 Dec;
PMID: 39643515
In this narrative review, we address the ongoing challenges of lung cancer (LC) screening using chest low-dose computerized tomography (LDCT) and explore the contributions of artificial intelligence (AI), in overcoming...
4.
Robertson J, Adanyeguh I, Bender B, Boesch S, Brunetti A, Cocozza S, et al.
bioRxiv
. 2024 Sep;
PMID: 39345594
Objective: Spinocerebellar ataxia type 2 (SCA2) is a rare, inherited neurodegenerative disease characterised by progressive deterioration in both motor coordination and cognitive function. Atrophy of the cerebellum, brainstem, and spinal...
5.
Mascalchi M, Cavigli E, Picozzi G, Cozzi D, De Luca G, Diciotti S
J Thorac Imaging
. 2024 Sep;
PMID: 39267479
Purpose: Lesion overlooking and late diagnostic workup can compromise the efficacy of low-dose CT (LDCT) screening of lung cancer (LC), implying more advanced and less curable disease stages. We hypothesized...
6.
Mascalchi M, Puliti D, Cavigli E, Cortes-Ibanez F, Picozzi G, Carrozzi L, et al.
Eur J Radiol
. 2024 Aug;
179:111679.
PMID: 39163805
Purpose: To investigate the early radiological features and survival of Large Cell Carcinoma (LCC) cases diagnosed in low-dose computed tomography (LDCT) screening trials. Methods: Two radiologists jointly reviewed the radiological...
7.
Manco C, Cortese R, Leoncini M, Plantone D, Gentile G, Luchetti L, et al.
J Neurol Sci
. 2024 Aug;
464:123163.
PMID: 39128160
Background: Vascular mild cognitive impairment (VMCI) is a transitional condition that may evolve into Vascular Dementia(VaD). Hippocampal volume (HV) is suggested as an early marker for VaD, the role of...
8.
Marfisi D, Giannelli M, Marzi C, Del Meglio J, Barucci A, Masturzo L, et al.
Magn Reson Imaging
. 2024 Jul;
113:110217.
PMID: 39067653
Radiomics of cardiac magnetic resonance (MR) imaging has proved to be potentially useful in the study of various myocardial diseases. Therefore, assessing the repeatability degree in radiomic features measurement is...
9.
Bisanzi S, Puliti D, Picozzi G, Romei C, Pistelli F, Deliperi A, et al.
Cancers (Basel)
. 2024 Jun;
16(12).
PMID: 38927981
The role of total plasma cell-free DNA (cfDNA) in lung cancer (LC) screening with low-dose computed tomography (LDCT) is uncertain. We hypothesized that cfDNA could support differentiation between malignant and...
10.
Cortes-Ibanez F, Johnson T, Mascalchi M, Katzke V, Delorme S, Kaaks R
Sci Rep
. 2024 Mar;
14(1):7197.
PMID: 38531926
Cardiac Troponin I (cTnI) could be used to identify individuals at elevated risk of cardiac death in lung cancer (LC) screening settings. In a population-based, randomized LC screening trial in...